Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Active not recruiting 2Recruiting 1Available 1

Sponsor Class

INDUSTRY 3NETWORK 1

Study Type

Interventional 3Expanded_access 1

Sponsor

Cancer Type

Plasma cell 5Sarcoma 4Tumor-Agnostic 1

Conditions

Desmoid Tumors 4

Interventions

Specimen Handling 36Magnetic Resonance Spectroscopy 31Cyclophosphamide 26Doxorubicin 23Biopsy 22pembrolizumab 21Temozolomide 21X-Rays 17Radiotherapy 17Radiation 16Nivolumab 13atezolizumab 12Vincristine 12Phantoms, Imaging 12Irinotecan 12Ifosfamide 12Gemcitabine 12fludarabine 11cabozantinib 10liposomal doxorubicin 8Surgical Procedures, Operative 8Ipilimumab 8Etoposide 8Bevacizumab 8Paclitaxel 7Immunoglobulin G 7Carboplatin 7palbociclib 6olaparib 6fludarabine phosphate 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
nirogacestat × Sarcoma × 90 days × Clear all
NCT05041036 2026-05-08

Individual Patient Compassionate Use of Nirogacestat

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Available
Sarcoma

Desmoid Tumors

NCT07170644 2026-05-08

A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 2 Active not recruiting
20 enrolled
Sarcoma

Desmoid Tumors

NCT07176689 2026-05-08

Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 4 Recruiting
50 enrolled
Sarcoma

Desmoid Tumors

NCT04195399 2026-04-15

A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

Children's Oncology Group

Phase 2 Active not recruiting
31 enrolled
Sarcoma

Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡